Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

Returns on capital

Akebia Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-16.4%

avg -222.9%

ROIC

9.3%

avg -41.8%

ROA

-1.4%

avg -32.4%

Analysis

ROIC is currently the strongest return metric at 9.3% versus its period average of -41.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

John Butler

Chief Executive Officer, President & DirectorUSD 1.46M62——

Carolyn Rucci

Senior Vice President, Chief Legal Officer & SecretaryUSD 933.3K45——

Steven Keith Burke

Senior Vice President and Chief Research & Development OfficerUSD 860.32K65948.43K0.35%

Erik John Ostrowski

Chief Business Officer, Senior Vice President, Chief Financial Officer & TreasurerUSD 792.87K54——

Nicholas Grund

Senior Vice President & Chief Commercial OfficerUSD 728.91K56561.75K0.21%

Justin McCue

Senior VP & Chief Technology Officer————

Mercedes Carrasco

Senior Director of Investor & Corporate Communications————

Richard C. Malabre

Senior VP & Chief Accounting Officer—65299.39K0.11%

Meredith Bowman

Senior Vice President & Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$86,587.50

Sells

16

$962,955.30

Net Transaction Value

−$876,367.80

Net selling

Most Active

Butler John P.

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 29, 26

Ostrowski Erik

Direct

Sell$62.2K
Mar 4, 26

Butler John P.

Direct

Buy$86.6K
Feb 2, 26

Malabre Richard C

Direct

Sell$50.2K
Feb 2, 26

Malabre Richard C

Direct

Sell$18.6K
Feb 2, 26

Grund Nicholas

Direct

Sell$74.5K
Feb 2, 26

Grund Nicholas

Direct

Sell$43.4K
Feb 2, 26

Burke Steven Keith

Direct

Sell$30K
Feb 2, 26

Burke Steven Keith

Direct

Sell$35.3K
Feb 2, 26

Burke Steven Keith

Direct

Sell$28.8K
Feb 2, 26

Rucci Carolyn M.

Direct

Sell$23.4K

1–10 of 17

Summary

Insiders reported 1 buys worth $86,587.50 and 16 sells worth $962,955.30 over the last 12 months. That adds up to net selling of $876,367.80. Butler John P. was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-6.9%
-9.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -6.9% over three years. Forward estimates point to Revenue at -9.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Akebia Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AKBA's management, answered from reported figures.

Who manages AKBA?

Akebia Therapeutics, Inc. (AKBA) lists 9 active executives. The top listed executive is Justin McCue, Senior VP & Chief Technology Officer.

Are AKBA insiders buying or selling?

Recent insider activity shows net buying of $15.90M.